John E. Davis Sells 6,457 Shares of Artivion, Inc. (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) insider John E. Davis sold 6,457 shares of Artivion stock in a transaction on Monday, February 24th. The stock was sold at an average price of $27.31, for a total value of $176,340.67. Following the sale, the insider now owns 160,631 shares in the company, valued at $4,386,832.61. This trade represents a 3.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Artivion Trading Down 0.2 %

Shares of Artivion stock opened at $25.38 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. The stock has a market capitalization of $1.06 billion, a P/E ratio of -1,268.85 and a beta of 1.75. Artivion, Inc. has a 52-week low of $18.38 and a 52-week high of $32.33. The stock’s 50-day simple moving average is $29.63 and its 200 day simple moving average is $27.81.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.51). The business had revenue of $97.31 million during the quarter, compared to the consensus estimate of $100.82 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. As a group, research analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. JMP Securities reiterated a “market outperform” rating and set a $33.00 target price on shares of Artivion in a research note on Tuesday, December 10th. Oppenheimer lifted their price objective on shares of Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Needham & Company LLC dropped their target price on shares of Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Stifel Nicolaus decreased their price target on shares of Artivion from $33.00 to $30.00 and set a “buy” rating for the company in a research note on Tuesday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Artivion has a consensus rating of “Buy” and a consensus target price of $31.40.

Hedge Funds Weigh In On Artivion

Large investors have recently made changes to their positions in the stock. Wellington Management Group LLP lifted its holdings in Artivion by 2.9% during the 3rd quarter. Wellington Management Group LLP now owns 1,656,264 shares of the company’s stock worth $44,090,000 after purchasing an additional 46,267 shares in the last quarter. Wasatch Advisors LP grew its holdings in Artivion by 27.7% during the 4th quarter. Wasatch Advisors LP now owns 1,041,992 shares of the company’s stock valued at $29,791,000 after buying an additional 226,160 shares in the last quarter. Next Century Growth Investors LLC increased its position in shares of Artivion by 29.7% during the fourth quarter. Next Century Growth Investors LLC now owns 492,653 shares of the company’s stock valued at $14,085,000 after buying an additional 112,918 shares during the period. Northern Trust Corp lifted its holdings in shares of Artivion by 10.0% in the fourth quarter. Northern Trust Corp now owns 463,250 shares of the company’s stock worth $13,244,000 after buying an additional 42,170 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Artivion by 2.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 358,192 shares of the company’s stock valued at $10,241,000 after acquiring an additional 8,343 shares during the period. 86.37% of the stock is owned by institutional investors.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.